Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. Weller M, et al. Among authors: goldbrunner r. Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5. Clin Cancer Res. 2015. PMID: 25655102 Free article. Clinical Trial.
Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.
Stegmann S, Werner JM, Kuhl S, Röhn G, Krischek B, Stavrinou P, Goldbrunner R, Timmer M. Stegmann S, et al. Among authors: goldbrunner r. Anticancer Res. 2019 May;39(5):2299-2306. doi: 10.21873/anticanres.13346. Anticancer Res. 2019. PMID: 31092421
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y. Di Tacchio M, et al. Among authors: goldbrunner r. Cancer Immunol Res. 2019 Dec;7(12):1910-1927. doi: 10.1158/2326-6066.CIR-18-0865. Epub 2019 Oct 9. Cancer Immunol Res. 2019. PMID: 31597643
Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.
Stegmann SK, Kuhl S, Im NG, Diem-Dinh DT, Goertz L, Goldbrunner R, Timmer M. Stegmann SK, et al. Among authors: goldbrunner r. Anticancer Res. 2022 Mar;42(3):1237-1245. doi: 10.21873/anticanres.15591. Anticancer Res. 2022. PMID: 35220214
244 results